SG11202004268PA - Use of a vegf antagonist to treat angiogenic eye disorders - Google Patents

Use of a vegf antagonist to treat angiogenic eye disorders

Info

Publication number
SG11202004268PA
SG11202004268PA SG11202004268PA SG11202004268PA SG11202004268PA SG 11202004268P A SG11202004268P A SG 11202004268PA SG 11202004268P A SG11202004268P A SG 11202004268PA SG 11202004268P A SG11202004268P A SG 11202004268PA SG 11202004268P A SG11202004268P A SG 11202004268PA
Authority
SG
Singapore
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
treat angiogenic
treat
Prior art date
Application number
SG11202004268PA
Inventor
Robert L Vitti
Alyson J Berliner
Karen Chu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64755724&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202004268P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202004268PA publication Critical patent/SG11202004268PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11202004268PA 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders SG11202004268PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762593033P 2017-11-30 2017-11-30
US201862644425P 2018-03-17 2018-03-17
US201862748782P 2018-10-22 2018-10-22
PCT/US2018/063025 WO2019108770A1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (1)

Publication Number Publication Date
SG11202004268PA true SG11202004268PA (en) 2020-06-29

Family

ID=64755724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004268PA SG11202004268PA (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Country Status (22)

Country Link
US (2) US10973879B2 (en)
EP (3) EP3716992B1 (en)
JP (2) JP7339248B2 (en)
KR (1) KR20200093621A (en)
CN (1) CN111465407A (en)
AU (1) AU2018375398A1 (en)
BR (1) BR112020010659A2 (en)
CA (1) CA3083611A1 (en)
DK (1) DK3716992T3 (en)
ES (1) ES2927049T3 (en)
HR (1) HRP20221335T1 (en)
HU (1) HUE059827T2 (en)
IL (1) IL274711A (en)
LT (1) LT3716992T (en)
MX (1) MX2020005166A (en)
PL (1) PL3716992T3 (en)
PT (1) PT3716992T (en)
RS (1) RS63703B1 (en)
SG (1) SG11202004268PA (en)
SI (1) SI3716992T1 (en)
WO (1) WO2019108770A1 (en)
ZA (1) ZA202002821B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012991A (en) 2006-04-07 2008-10-17 Procter & Gamble Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof.
KR20180023015A (en) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. Use of a vegf antagonist to treat angiogenic eye disorders
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
DK3716992T3 (en) 2017-11-30 2022-09-12 Regeneron Pharma Use of a VEGF antagonist in the treatment of angiogenic eye disorders
EP3790532A1 (en) 2018-05-10 2021-03-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
TW202313095A (en) * 2021-05-17 2023-04-01 美商再生元醫藥公司 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US20230295266A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
ATE293164T1 (en) 1999-06-08 2005-04-15 Regeneron Pharma MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOCYNETIC PROPERTIES
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
EP2319492A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
KR20180023015A (en) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. Use of a vegf antagonist to treat angiogenic eye disorders
US20160130321A1 (en) * 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
BR112018005737A2 (en) 2015-09-23 2018-10-09 Genentech Inc antibodies, polynucleotide, vector, host cell, method for producing antibody, for reducing or inhibiting angiogenesis, for treating a disorder associated with angiogenesis, for inhibiting vascular permeability, composition, antibody conjugate, fusion protein, for identifying a change residues, antibody use, conjugate use and protein use
WO2017087798A1 (en) * 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
DK3716992T3 (en) 2017-11-30 2022-09-12 Regeneron Pharma Use of a VEGF antagonist in the treatment of angiogenic eye disorders
EP3790532A1 (en) 2018-05-10 2021-03-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations

Also Published As

Publication number Publication date
EP3716992A1 (en) 2020-10-07
CA3083611A1 (en) 2019-06-06
ES2927049T3 (en) 2022-11-02
DK3716992T3 (en) 2022-09-12
CN111465407A (en) 2020-07-28
SI3716992T1 (en) 2022-10-28
RS63703B1 (en) 2022-11-30
US20190290725A1 (en) 2019-09-26
EP3716992B1 (en) 2022-08-10
ZA202002821B (en) 2021-08-25
WO2019108770A1 (en) 2019-06-06
HRP20221335T1 (en) 2022-12-23
HUE059827T2 (en) 2023-01-28
BR112020010659A2 (en) 2020-11-10
EP4122486A1 (en) 2023-01-25
PT3716992T (en) 2022-08-31
JP2023159323A (en) 2023-10-31
MX2020005166A (en) 2020-09-03
JP2021505535A (en) 2021-02-18
PL3716992T3 (en) 2022-12-19
US20210205410A1 (en) 2021-07-08
US10973879B2 (en) 2021-04-13
AU2018375398A1 (en) 2020-06-18
EP4279135A2 (en) 2023-11-22
JP7339248B2 (en) 2023-09-05
IL274711A (en) 2020-07-30
EP4279135A3 (en) 2024-02-21
KR20200093621A (en) 2020-08-05
LT3716992T (en) 2022-09-12

Similar Documents

Publication Publication Date Title
IL274711A (en) Use of a vegf antagonist to treat angiogenic eye disorders
IL260167A (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK1231417A1 (en) Compounds for treating ophthalmic diseases and disorders
IL249602A0 (en) Methods and devices for treating posterior ocular disorders
GB201610695D0 (en) Eye massaging device
SG11201506309SA (en) Eye massager
TWD174587S (en) Portion of a massage device
SG11201608257RA (en) A device for a medical treatment of a sclera
ZA201702403B (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
IL267229A (en) Methods of treating ocular disorders
HK1205924A1 (en) Eye massager
HK1222535A1 (en) Lower-limb massage device
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL271164A (en) Use of vibegron to treat overactive bladder
EP3574907C0 (en) A dual nk-1/nk-3 receptor antagonist for the treatment of sex-hormone-dependent diseases
IL270362B (en) Treatment of glaucoma
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
PL3047824T3 (en) Device for laser treatment of a human eye
HK1220144A1 (en) Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl- phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases n-(4--)-3--n-[2-(4--3--)-]-2--5--
IL234962A0 (en) Use of agents for treating fat-related disorders
EP3506925C0 (en) Use of cgrp receptor antagonists in treating glaucoma
GB201604359D0 (en) Treatment of tissue disorders
SG11201709221QA (en) Lower limb exercise assisting device
GB201602641D0 (en) Treatment of fibrotic disorders